Accessibility Menu
Nika Pharmaceuticals logo

Nika Pharmaceuticals(OTC) NIKA

Market Cap$222.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-95%
5 YearN/A
1 Year-41%
1 Month-72%
$0.21
+0.00%
+0.00Today
Nika Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.212026-07-31
Nika Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-72.39%USD 0.772026-07-02
1 month-72.39%USD 0.772026-06-30
3 month-47.19%USD 0.402026-04-24
Year to date-44.15%USD 0.382025-12-30
1 year-40.61%USD 0.362025-07-29
Since inception-94.5%USD 13.992024-03-14

Nika Pharmaceuticals Financials at a Glance

Market Cap

$222.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$76.81K

EPS (TTM)

-$0.00

P/E Ratio

-2123.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.21

Volume

100

Open

$0.21

Previous Close

$0.21

Daily Range

$0.21 - $0.21

52-Week Range

$0.20 - $0.96

Estimated Earnings Date

Sep 22, 2025

NIKA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nika Pharmaceuticals

Nika Pharmaceuticals develops drugs and supplements for diseases like HIV and diabetes. Its products aim to help patients manage chronic conditions. The company works through partnerships and does not own manufacturing facilities.

What’s in the Medicine Cabinet?

  • Antiviral Drugs: Thymus Nuclear Glycoprotein for HIV treatment; no revenue generated yet.
  • Generic Medicines: Includes Menthyl Valerate, Metamizole Sodium, and Vinpocetine; all pre-commercialization.
  • Dietary Supplements: Carotilen, Physiolong, and others for immune support and recovery; no sales reported.
  • Licensing and Rights: Holds exclusive rights for several drugs and supplements; revenue contribution is 0% as of 2025.
  • Contract Manufacturing: Relies on third-party partners for production; no direct manufacturing operations.

Growth Spurts and Growing Pains

  • 2022–2024: Signed exclusive rights and joint venture agreements with VITAL FE, MICAR 11, and Immunotech Laboratories BG.
  • 2024: Acquired generic drug and supplement technologies from Alliance for Intellectual Property in the Field of Pharmacy, Chemistry, and Biology.
  • 2024: Entered supply agreement for vial production equipment with Nika Europe, Ltd..
  • 2024: Briefly acquired, then reversed ownership of Nika Pharmaceuticals, Ltd. and related factory assets.
  • 2024: Expanded product pipeline with new supplement and drug technologies.

Why Nika Stands Out (or Sits Down)

Nika operates globally through exclusive rights and joint ventures, covering multiple continents. Its asset-light model avoids direct manufacturing, relying on partners for production and distribution. The company’s structure allows flexibility but creates dependence on third parties and related party financing.

Five Things You Need to Know

  • No revenue reported for 2025 or 2024; all activities are pre-commercialization.
  • Net loss was $76,398 in 2025, improving 20.2% from 2024.
  • Cash at year-end 2025 was $1,889, with $318,624 owed to related parties.
  • CEO owns 42.54% of common stock and all preferred shares as of 2025.
  • Auditors express doubt about ongoing operations due to lack of revenue and negative working capital.

Bottom Line

Nika remains in a pre-revenue stage, focused on building partnerships and exclusive rights. Its future depends on converting its pipeline into commercial products and securing stable financing.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Henderson, NV 89044, US

NIKA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

27.39%

Return on Capital

N/A

Return on Assets

-372.21%

Earnings Yield

-0.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$222.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.05B

Volume

100

Avg. Volume

83.143

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$76.81K

EBITDA

-$76.81K

Operating Cash Flow

-$80.07K

Capital Expenditure

$0.00

Free Cash Flow

-$80.07K

Cash & ST Invst.

$1.53K

Total Debt

$0.00

Nika Pharmaceuticals Performance Analysis

Nika Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Nika Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Nika Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.00620.0%
20232023-12-31USD -0.00-97.2%
20242024-12-31USD -0.000.0%
20252025-12-31USD -0.000.0%
Nika Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$222.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-$13.36K

-3.2%

EBITDA

-$13.36K

-3.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.53K

-92.0%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-3.72%

N/A

Return on Invested Capital

24.70%

N/A

Free Cash Flow

-$13.36K

-3.2%

Operating Cash Flow

-$13.36K

-3.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CMVLFCellectis S.A.
$3.47+12.66%
EDTXFSpectral Medical Inc
$0.99-0.60%
COGZFCogstate Limited
$1.75+0.00%
CPHRFCipher Pharmaceuticals Inc.
$11.94+3.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About NIKA

What is the current price of Nika Pharmaceuticals?

Nika Pharmaceuticals is trading at $0.21 per share.

What is the 52-week range for Nika Pharmaceuticals?

Over the past 52 weeks, Nika Pharmaceuticals has traded between $0.20 and $0.96.

How much debt does Nika Pharmaceuticals have?

As of the most recent reporting period, Nika Pharmaceuticals reported total debt of $0.00.

How much cash does Nika Pharmaceuticals have on hand?

Nika Pharmaceuticals reported $1.53K in cash and cash equivalents in its most recent financial results.

What is Nika Pharmaceuticals’s dividend yield?

Nika Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services